Soliqua 100/33 33 ug/mL

Soliqua 100/33 is a combination of insulin glargine and lixisenatide, designed for subcutaneous administration. This medication is used to manage blood sugar levels in adults with type 2 diabetes. It combines long-acting insulin with a GLP-1 receptor agonist for comprehensive diabetes care.

Soliqua 100/33 is primarily used for the management of type 2 diabetes in adults. This medication works by combining insulin glargine, which provides a steady release of insulin over 24 hours, with lixisenatide, a GLP-1 receptor agonist that helps lower blood sugar levels by increasing insulin secretion and reducing glucagon release. People often ask, 'What is Soliqua 100/33 used for?' It is typically prescribed for individuals who require both types of medication to achieve better glycemic control.

Common effects of Soliqua 100/33 may include nausea, vomiting, diarrhea, and injection site reactions. Some users might experience hypoglycemia, or low blood sugar, especially if meals are skipped or if the dosage is not adjusted properly. It is important to monitor blood sugar levels regularly while using this medication.

Soliqua 100/33 should be handled with care and stored as directed to maintain its efficacy. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should not be shared with others, even if they have similar symptoms. Always check the label and expiration date before use.

Soliqua 100/33 may interact with other medications, including those that affect blood sugar levels, such as oral hypoglycemic agents, corticosteroids, and certain antidepressants. Alcohol consumption can also affect blood sugar levels and should be monitored carefully. It is advisable to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.